Novo Nordisk: Recovery Supported by Sector Tailwind and Hope in Alzheimer's Study

Market environment improves On Wednesday, the stock of Novo Nordisk rises by about 3%. Investors take advantage of the recent downturn following profit warnings, a CEO change, and a downgrade by Morgan Stanley to enter the market. This recovery is supported by a favorable industry environment: the European healthcare sector is among the day's winners. Particularly, the FDA approval of a Novartis drug and the easing of concerns over massive drug price intervention in the USA boost sentiment. The background is an agreement between Pfizer and US...